Halozyme Therapeutics (HALO) Return on Equity (ROE) (2011 - 2026)
Halozyme Therapeutics (HALO) Return on Equity (ROE) from Jun 30, 2011 to Mar 31, 2026. The TTM Halozyme Therapeutics (HALO) Return on Equity (ROE) is 68.32%. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual ROE
Quarterly ROE
Annual Return on Equity (ROE) change of Halozyme Therapeutics (HALO)
| Year | Return on Equity (ROE) | Change |
|---|---|---|
| 2025 | 649.23% | +431.88% |
| 2024 | 122.06% | -63.67% |
| 2023 | 335.99% | +182.25% |
| 2022 | 119.04% | -41.78% |
| 2021 | 204.47% | +139.26% |
| 2020 | 85.46% | -208.57% |
| 2019 | -78.72% | +143.90% |
| 2018 | -32.28% | -206.80% |
| 2017 | 30.22% | -90.47% |
| 2016 | 317.18% | -523.17% |
| 2015 | -74.95% | -54.67% |
| 2014 | -165.34% | -139.59% |
| 2013 | 417.61% | -481.03% |
| 2012 | -109.60% | -39.57% |
| 2011 | -181.38% | -30.67% |
| 2010 | -261.62% | -69.07% |
| 2009 | -845.80% | N/A |